{
    "other_tests": [
        {
            "procedure_name": "Leuprolide acetate stimulation test",
            "date": "Not specified",
            "findings": {
                "baseline_FSH": "< 1.0 mIU/ml",
                "baseline_LH": "< 1.0 mIU/ml",
                "3h_post_stimulation_FSH": "3.4 mIU/ml",
                "3h_post_stimulation_LH": "2.0 mIU/ml",
                "3h_post_stimulation_estradiol": "9 pg/ml"
            },
            "changes_over_time": "Not specified"
        },
        {
            "procedure_name": "Transvaginal ultrasound",
            "date": "Not specified",
            "findings": {
                "right_ovary_size": "17 mm x 12 mm",
                "left_ovary_size": "18 mm x 13 mm",
                "AFC": 0
            },
            "changes_over_time": "Not specified"
        },
        {
            "procedure_name": "hMG treatment cycles",
            "date": "Cycle 1 to Cycle 3 (16 weeks course)",
            "findings": [
                {
                    "cycle": 1,
                    "AMH": "0.20 ng/ml",
                    "AFC": 0
                },
                {
                    "cycle": 2,
                    "AMH": "1.02 ng/ml",
                    "AFC": 4
                },
                {
                    "cycle": 3,
                    "AMH": "1.26 ng/ml",
                    "AFC": 6
                }
            ],
            "changes_over_time": "AMH levels increased from 0.20 ng/ml to 1.26 ng/ml over three cycles of hMG treatment."
        }
    ]
}